Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts' Opinion using a Delphi Approach.
Schizophrenia
cariprazine
metabolism
negative symptoms
positive symptoms
quality of life
switch
Journal
Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
11
2022
revised:
06
01
2023
accepted:
13
01
2023
pmc-release:
01
03
2024
medline:
11
9
2023
pubmed:
20
7
2023
entrez:
20
7
2023
Statut:
ppublish
Résumé
Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability. To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique. A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%). Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data. These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.
Sections du résumé
BACKGROUND
BACKGROUND
Schizophrenia is a psychiatric disorder whose therapeutic objectives are aimed at reducing symptoms and improving patient's quality of life. First- and second-generation antipsychotics present numerous side effects. Recently introduced in the treatment of schizophrenia, cariprazine has shown to improve positive and negative symptoms as well as cognitive impairment, with good tolerability.
OBJECTIVE
OBJECTIVE
To assess the level of consensus among Italian psychiatrists in relation to the use of cariprazine in the treatment of schizophrenia by using the Delphi technique.
METHOD
METHODS
A Delphi study was undertaken between January and July 2022. Two questionnaires were consecutively sent to a panel of 97 psychiatrists from all over Italy, of which 81 actively participated, anonymously, in at least one of the two consultations with a sufficiently high response rate (83%).
RESULTS
RESULTS
Broad consensus in terms of the efficacy and safety of cariprazine in the treatment of schizophrenia during all phases of the disorder. The young first-episode schizophrenia patient with or without substance abuse seems to be an excellent candidate for cariprazine therapy. In addition, the lack of side effects makes cariprazine a suitable drug for adult and elderly patients with schizophrenia. However, there is still limited experience with the use of cariprazine, along with little knowledge of the most recent real-life data.
CONCLUSION
CONCLUSIONS
These results could encourage wider dissemination of evidence-based practices with the final aim of optimizing the clinical use of cariprazine in patients with schizophrenia.
Identifiants
pubmed: 37469149
pii: CN-EPUB-133025
doi: 10.2174/1570159X21666230719162023
pmc: PMC10556386
doi:
Substances chimiques
cariprazine
F6RJL8B278
Antipsychotic Agents
0
Piperazines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2206-2216Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Références
NPJ Schizophr. 2021 Feb 15;7(1):11
pubmed: 33589645
Am J Psychiatry. 2020 Apr 1;177(4):342-353
pubmed: 31838873
Int Clin Psychopharmacol. 2017 Nov;32(6):319-328
pubmed: 28692485
Neuropsychiatr Dis Treat. 2021 Apr 07;17:957-970
pubmed: 33854317
Drugs. 2020 Nov;80(17):1763-1781
pubmed: 32930957
Neuropsychiatr Dis Treat. 2018 Oct 05;14:2563-2577
pubmed: 30323605
Front Psychiatry. 2020 Mar 03;11:61
pubmed: 32194443
Riv Psichiatr. 2019 Nov-Dec;54(6):11-15
pubmed: 32310934
Am J Psychiatry. 2020 Sep 1;177(9):868-872
pubmed: 32867516
Front Psychiatry. 2022 Jan 05;12:770234
pubmed: 35069278
Curr Top Med Chem. 2021 Oct 25;21(16):1500-1516
pubmed: 34218785
CNS Spectr. 2018 Feb;23(1):39-50
pubmed: 28478771
Riv Psichiatr. 2019 Nov-Dec;54(6):7-10
pubmed: 32310933
Riv Psichiatr. 2019 Nov-Dec;54(6):16-19
pubmed: 32310935
Neuropsychiatr Dis Treat. 2019 Jun 05;15:1525-1535
pubmed: 31239687
Front Psychiatry. 2022 Jan 25;12:781946
pubmed: 35145438
J Psychopharmacol. 2020 Jan;34(1):3-78
pubmed: 31829775
Riv Psichiatr. 2019 Nov-Dec;54(6):1-6
pubmed: 32310932
Psychopharmacol Bull. 2020 Sep 14;50(4):83-117
pubmed: 33012874
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178
pubmed: 33508803
Ther Adv Psychopharmacol. 2021 May 10;11:20451253211012250
pubmed: 34025981
J Clin Psychiatry. 2019 Jan 8;80(2):
pubmed: 30695290
Int J Psychiatry Clin Pract. 2017 Jun;21(2):82-90
pubmed: 28498090
CNS Drugs. 2020 May;34(5):473-507
pubmed: 32246399
Ann Gen Psychiatry. 2020 Sep 26;19:55
pubmed: 32999683
Int J Environ Res Public Health. 2021 Dec 19;18(24):
pubmed: 34948983
World J Methodol. 2021 Jul 20;11(4):116-129
pubmed: 34322364
Neuropsychiatr Dis Treat. 2021 Dec 07;17:3581-3588
pubmed: 34908838